Scribe Therapeutics Inc. (SCTX)
NASDAQ: SCTX · Real-Time Price · USD
19.39
-0.69 (-3.44%)
At close: Oct 19, 2026, 4:00 PM EDT
19.46
+0.07 (0.36%)
After-hours: Oct 19, 2026, 7:30 PM EDT
Scribe Therapeutics Revenue
Scribe Therapeutics had revenue of $1.92M in the quarter ending June 30, 2026. This brings the company's total for the last twelve months to $33.30M. In the year 2025, Scribe Therapeutics had annual revenue of $51.17M with 86.68% growth. That makes Scribe Therapeutics the 30,699th largest company in the world by revenue and 4,056th in the United States.
Revenue (ttm)
$33.30M
Revenue Growth
+86.68%
P/S Ratio
11.02
Revenue / Employee
$406,122
Employees
82
Market Cap
367.09M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 51.17M | 23.76M | 86.68% |
| Dec 31, 2024 | 27.41M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
SCTX News
- 26 days ago - Cathie Wood’s ARK Investment buys 143.3K shares of Scribe Therapeutics today - TheFly
- 6 weeks ago - Scribe Therapeutics reports Q2 EPS ($2.62), consensus ($3.72) - TheFly
- 6 weeks ago - Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 6 weeks ago - Scribe Therapeutics Earnings release: Q2 2026 - Filings
- 6 weeks ago - Scribe Therapeutics Quarterly report: Q2 2026 - Filings
- 6 weeks ago - Scribe Therapeutics Slides: Investor presentation - Filings
- 6 weeks ago - Scribe Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 7 weeks ago - Scribe Therapeutics initiated with a Buy at H.C. Wainwright - TheFly